Reviewer's report
Title:Likelihood of complete response for advanced liver cancer during sorafenib
therapy: Case Report
Version: 2Date:23 September 2010
Reviewer: GHASSAN ABOU-ALFA
Reviewer's report:
This is a case report of a patient with a complete response allegedly secondary
to sorafenib.
Minor but essential revisions:
The authors present a well written manuscript and report clearly the limitation of
their evaluation, especially the lack of a biopsy. They should however report in
the case presentation which diagnostic criteria were used and if they were all
met.
The authors bring up in the discussion another variable about the age of the
patient and tolerability of the drug. As this is not the subject of discussion and
patients are prescribed cancer care based on performance rather than age, it is
suggested to tone down this piece
However a more important piece about sorafenib effect on modulation of
pro-thrombotic cytokines should be elaborated on further
Lastly it would be valuable if the authors comment on the status of the arterial
vasculature as resolution of liver masses accompanied by the development of an
arterial thrombus is well noted in the literature.
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
- Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially from the
publication of this paper, either now or in the future?
Yes research support from Bayer
Advisory to Bayer
Reviewer's report
Title:Likelihood of complete response for advanced liver cancer during sorafenib
therapy: Case Report
Version: 2Date:23 September 2010
Reviewer: GHASSAN ABOU-ALFA
Reviewer's report:
This is a case report of a patient with a complete response allegedly secondary
to sorafenib.
Minor but essential revisions:
The authors present a well written manuscript and report clearly the limitation of
their evaluation, especially the lack of a biopsy. They should however report in
the case presentation which diagnostic criteria were used and if they were all
met.
The authors bring up in the discussion another variable about the age of the
patient and tolerability of the drug. As this is not the subject of discussion and
patients are prescribed cancer care based on performance rather than age, it is
suggested to tone down this piece
However a more important piece about sorafenib effect on modulation of
pro-thrombotic cytokines should be elaborated on further
Lastly it would be valuable if the authors comment on the status of the arterial
vasculature as resolution of liver masses accompanied by the development of an
arterial thrombus is well noted in the literature.
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
- Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially from the
publication of this paper, either now or in the future?
Yes research support from Bayer
Advisory to Bayer
Please review this paper.
user
Reviewer's report
Title:Likelihood of complete response for advanced liver cancer during sorafenib
therapy: Case Report
Version: 2Date:23 September 2010
Reviewer: GHASSAN ABOU-ALFA
Reviewer's report:
This is a case report of a patient with a complete response allegedly secondary
to sorafenib.
Minor but essential revisions:
The authors present a well written manuscript and report clearly the limitation of
their evaluation, especially the lack of a biopsy. They should however report in
the case presentation which diagnostic criteria were used and if they were all
met.
The authors bring up in the discussion another variable about the age of the
patient and tolerability of the drug. As this is not the subject of discussion and
patients are prescribed cancer care based on performance rather than age, it is
suggested to tone down this piece
However a more important piece about sorafenib effect on modulation of
pro-thrombotic cytokines should be elaborated on further
Lastly it would be valuable if the authors comment on the status of the arterial
vasculature as resolution of liver masses accompanied by the development of an
arterial thrombus is well noted in the literature.
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
- Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially from the
publication of this paper, either now or in the future?
Yes research support from Bayer
Advisory to Bayer
assistant